Tweet
PPIs Linked to Lower Cognitive Decline in Latest Study
Sue Hughes
June 22, 2017
A new study has smoothed the waters somewhat over concerns about a possible increased risk for dementia with proton-pump inhibitors (PPIs).
In this latest observational, longitudinal study, individuals without dementia at baseline who were taking PPIs had a lower risk for cognitive decline than those were not taking PPIs.
In addition, both consistent and intermittent use of PPIs was associated with lower risk for cognitive decline with a suspected Alzheimer's cause, and the same finding of a lower risk for cognitive decline in those taking PPIs was observed for individuals with normal cognition or mild cognitive impairment at baseline.
"The current findings do not support that PPIs are associated with greater risk of dementia despite mechanisms proposed as to why they should be," lead author, Felicia C. Goldstein, PhD, Emory University, Atlanta, Georgia, and colleagues conclude.
Proposed mechanisms include PPIs being associated with higher β-amyloid levels in a mouse model and an association between use of PPIs and vitamin B12 deficiency. In addition, certain PPIs, including lansoprazole and omeprazole, cross the blood
Sue Hughes
June 22, 2017
A new study has smoothed the waters somewhat over concerns about a possible increased risk for dementia with proton-pump inhibitors (PPIs).
In this latest observational, longitudinal study, individuals without dementia at baseline who were taking PPIs had a lower risk for cognitive decline than those were not taking PPIs.
In addition, both consistent and intermittent use of PPIs was associated with lower risk for cognitive decline with a suspected Alzheimer's cause, and the same finding of a lower risk for cognitive decline in those taking PPIs was observed for individuals with normal cognition or mild cognitive impairment at baseline.
"The current findings do not support that PPIs are associated with greater risk of dementia despite mechanisms proposed as to why they should be," lead author, Felicia C. Goldstein, PhD, Emory University, Atlanta, Georgia, and colleagues conclude.
Proposed mechanisms include PPIs being associated with higher β-amyloid levels in a mouse model and an association between use of PPIs and vitamin B12 deficiency. In addition, certain PPIs, including lansoprazole and omeprazole, cross the blood